Description

KPV 10 mg — α-MSH-Derived Anti-Inflammatory Tripeptide for Mucosal & Skin Research

KPV is a synthetic tripeptide consisting of lysine, proline, and valine (Lys-Pro-Val) — derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). In preclinical research, KPV has been studied for its anti-inflammatory, anti-microbial, and mucosal-protective properties, with particular interest in models of inflammatory bowel disease, skin inflammation, and barrier dysfunction.

What It Is

• Class: Tripeptide derived from α-MSH (amino acids 11–13)
• Concept: A short, stable peptide fragment that retains anti-inflammatory and immunomodulatory activity of its parent α-MSH molecule without the broader melanocortin-receptor effects, offering researchers a focused tool for inflammation pathway studies.
• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

Anti-Inflammatory Signaling

• Modulates NF-κB signaling pathways, a central regulator of inflammatory gene expression.
• Reduces expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in research models.
• Investigations into effects on macrophage polarization and immune cell activation states.

Mucosal Barrier & Anti-Microbial Effects

• Research explores effects on intestinal epithelial integrity and tight junction protein expression.
• Studies on anti-microbial activity against bacterial and fungal pathogens in vitro.
• Investigations into mucosal healing in models of colitis and inflammatory bowel disease.
• Examination of effects on skin barrier function in inflammatory dermatology models.

Selected Research Highlights

• Inflammatory Bowel Disease Research: KPV has been investigated for effects on colitis models, including studies of oral delivery, nanoparticle delivery systems, and topical mucosal application.
• Skin Inflammation Studies: Research on atopic dermatitis, psoriasis, and other inflammatory skin condition models.
• Anti-Microbial Investigations: Studies examining activity against Staphylococcus aureus, Candida albicans, and other pathogens in laboratory settings.
• Mucosal Healing: Animal models exploring KPV’s effects on epithelial recovery following chemical or inflammatory injury.

Chemical & Handling Information

• Type: Synthetic tripeptide (3-amino-acid sequence)
• Backbone: L-Lysyl-L-Prolyl-L-Valine (Lys-Pro-Val) — corresponds to residues 11–13 of α-MSH (exact sequence per lot specification)
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide: KPV (Lys-Pro-Val)
• Amount: 10 mg per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.